FINWIRES · TerminalLIVE
FINWIRES

Hybio Pharma Ties Up With Sunshine Mandi for Semaglutide Injection Commercialization

By

Hybio Pharmaceutical (SHE:300199) signed a cooperation agreement with Zhejiang Sunshine Mandi Pharmaceutical for the development and marketing of products related to semaglutide injection, according to a Shenzhen bourse filing on Thursday.

Both parties will co-develop a semaglutide injection in a cartridge with an adjustable injection pen, which will cater to adult patients with type 2 diabetes mellitus.

The Chinese pharmaceutical company will receive an upfront signing payment of 12 million yuan from Sunshine Mandi, then 18 million yuan upon the drug regulator's approval and 7.5 million yuan upon approval of the first commercial batch.

Sunshine Mandi will be given exclusive rights to market the product in China region.

Hybio completed the phase III clinical trial of semaglutide injection in China.

Hybio's shares rose 2% at the close.

Related Articles

Asia

Grand Korea Leisure to Invest KRW168.8 Billion to Renew Gangnam COEX Lease Through 2035

Grand Korea Leisure (KRX:114090) plans to invest 168.8 billion won to renew the lease for its existing Gangnam COEX business site upon expiration of the current lease agreement, according to a Thursday filing with the Korea Exchange.The new facility investment aims to ensure stable operations across the business site and maintain the operating base. The investment covers lease payments for the period through Oct. 4, 2035, excluding value-added tax, management fees, taxes, and public dues, the filing said.The new lease agreement is scheduled to be valid from Aug. 21, it said.Shares of the casino operator fell nearly 4% in recent trade.

KRX:114090
Asia

Sunwoda Electronic to Invest 4 Million Yuan to Set Up Joint Venture

Sunwoda Electronic (SHE:300207) agreed to invest 4 million yuan to establish a joint venture with three other investors, according to a Shenzhen bourse filing on Thursday.The venture, Shenzhen Xincheng Digital Services, will have a registered capital of 10 million yuan and will be developing software and services related to blockchain technology and other internet services, as well as offer services in engineering and technology, natural sciences and industrial design.The company will own 40% of the venture.Shenzhen Dianlian Technology, Shenzhen Li'an Technology and Shenzhen Xincheng Zhiyuan Enterprise Management Partnership (Limited Partnership) are the other joint venture partners, holding 20%, 10% and 30%, respectively.The lithium-ion battery maker's shares fell 1% during the morning trade.

SHE:300207
Asia

Doosan Fuel Cell Wins Four Fuel Cell System Supply, Services Contracts; Shares Jump 8%

Doosan Fuel Cell (KRX:336260) secured four fuel cell system supply and service contracts from YH Power 1 and YH Power 2, according to several filings with the Korea Exchange on Thursday.The fuel cell system supply contract and a long-term service agreement (LTSA) for fuel cell systems with YH Power 1 are valued at 31 billion won and 28.8 billion won, respectively. The contract for the fuel cell system supply is valid till March 31, 2028, and the LTSA is valid till March 31, 2048, the filing said.The fuel cell system supply contract and the LTSA for fuel cell systems with YH Power 2 are valued at 29.6 billion won and 27.5 billion won, respectively. The contract for the fuel cell system supply is valid till March 31, 2028, and the LTSA is valid till March 31, 2048, it said.Shares of Doosan Fuel Cell added nearly 8% in recent trade.

KRX:336260